Rank 21 • Biotech & Discovery
Insilico Medicine
Utilizes generative AI to discover novel targets and design clinical-stage drug candidates across multiple therapeutic areas.
Visit website- Signal Score
- 90.7
- Total raised
- $400M
- Stage
- Series D+
- Founded
- 2014
- Headquarters
- Hong Kong
- Region
- Asia-Pacific
Their signal
Insilico pioneered the transition of generative AI molecules from computer models into human clinical trials. Its advanced chemistry and biology pipelines make it a primary standard-bearer for AI-based drug design.
Signal Score 90.7editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Did we miss something?
Change, add or remove details on this company. Our desk reviews every request.
Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.